These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1115 related items for PubMed ID: 33401940

  • 1. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R.
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [Abstract] [Full Text] [Related]

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 3. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA, Pinner NA.
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [Abstract] [Full Text] [Related]

  • 4. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 5. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ, Butler J, Kosiborod MN.
    Am J Med; 2024 Feb 19; 137(2S):S25-S34. PubMed ID: 38184323
    [Abstract] [Full Text] [Related]

  • 6. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
    Blair HA.
    Am J Cardiovasc Drugs; 2021 Nov 19; 21(6):701-710. PubMed ID: 34651263
    [Abstract] [Full Text] [Related]

  • 7. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA, Pinner NA, Lisenby KM, Osmonson A.
    Pharmacotherapy; 2021 Jun 19; 41(6):526-536. PubMed ID: 33866578
    [Abstract] [Full Text] [Related]

  • 8. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M, D'Amario D, Sofia C, Vaccarella M, Crea F, Aspromonte N.
    Expert Opin Drug Metab Toxicol; 2018 Dec 19; 14(12):1273-1285. PubMed ID: 30472914
    [Abstract] [Full Text] [Related]

  • 9. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ, Brunton SA, Rangaswami J.
    Cardiovasc Diabetol; 2023 Nov 16; 22(1):316. PubMed ID: 37974185
    [Abstract] [Full Text] [Related]

  • 10. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB, McCullough PA.
    Cardiorenal Med; 2022 Nov 16; 12(3):81-93. PubMed ID: 35835083
    [Abstract] [Full Text] [Related]

  • 11. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E, Verma S.
    Can J Cardiol; 2021 Apr 16; 37(4):669-673. PubMed ID: 33450364
    [Abstract] [Full Text] [Related]

  • 12. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB.
    Adv Ther; 2022 Aug 16; 39(8):3472-3487. PubMed ID: 35699903
    [Abstract] [Full Text] [Related]

  • 13. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.
    Circulation; 2019 May 28; 139(22):2528-2536. PubMed ID: 30882238
    [Abstract] [Full Text] [Related]

  • 14. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y, Kuwahara K.
    J Cardiol; 2020 Aug 28; 76(2):123-131. PubMed ID: 32340780
    [Abstract] [Full Text] [Related]

  • 15. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
    Hsiao FC, Lin CP, Tung YC, Chang PC, McMurray JJV, Chu PH.
    Int J Cardiol; 2021 May 01; 330():91-97. PubMed ID: 33587940
    [Abstract] [Full Text] [Related]

  • 16. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S.
    ESC Heart Fail; 2022 Apr 01; 9(2):942-946. PubMed ID: 35112512
    [Abstract] [Full Text] [Related]

  • 17. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.
    Yankah RK, Anku EK, Eligar V.
    J Diabetes Res; 2024 Apr 01; 2024():9985836. PubMed ID: 38766320
    [Abstract] [Full Text] [Related]

  • 18. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE, Ahuja T, Bridgeman MB.
    Ann Pharmacother; 2018 Dec 01; 52(12):1238-1249. PubMed ID: 29911393
    [Abstract] [Full Text] [Related]

  • 19. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV, Mather PJ.
    Ther Adv Cardiovasc Dis; 2021 Dec 01; 15():17539447211002678. PubMed ID: 33779401
    [Abstract] [Full Text] [Related]

  • 20. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D, Mazer CD, Stakos D, Tzifa A, Loggos S, Verma S, Mitropoulos F.
    Curr Pharm Des; 2021 Dec 01; 27(8):1051-1060. PubMed ID: 33143620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.